Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis

Cancer Research

Volumn 64, Issue 12, 2004, Pages 4180-4189

  Zhang, Li ^a,b   Hill, Richard P ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; FIBROSARCOMA; GENE CONTROL; GENE OVEREXPRESSION; HYPOXIA; METASTASIS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TRANSACTIVATION;

ANIMALS; APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; DNA, ANTISENSE; FIBROSARCOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C3H; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 3042616216     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3038     Document Type: Article

References (67)

1. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003;20(3):237-50.
2. Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000; 76(5):589-605.
3. Pitson G, Fyles A, Milosevic M, Wylie J, Pintilie M, Hill R. Tumor size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer. Int J Radiat Oncol Biol Phys 2001;51(3):699-703.
4. Sundfor K, Lyng H, Rofstad EK. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer 1998; 78(6):822-7.
5. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56(5): 941-3.
6. Walenta S, Wetterling M, Lehrke M, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000;60(4):916-21.
7. Nordsmark M, Alsner J, Keller J, et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84(8):1070-5.
8. Young SD, Marshall RS, Hill RP. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci USA 1988; 85(24):9533-7.
9. Young SD, Hill RP. Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. J Natl Cancer Inst (Bethesda) 1990;82(5):371-80.
10. Rofstad EK, Danielsen T. Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer 1999;80(11):1697-707.
11. Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 2000; 60(17):4932-8.
12. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999;5(11):3711-21.
13. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 1996;56(24):5594-9.
14. Wong CW, Lee A, Shientag L, et al. Apoptosis: an early event in metastatic inefficiency. Cancer Res 2001;61(1):333-8.
15. Inbal B, Cohen O, Polak-Charcon S, et al. DAP kinase links the control of apoptosis to metastasis. Nature (Lond.) 1997;390(6656):180-4.
16. Takaoka A, Adachi M, Okuda H, et al. Anti-cell death activity promotes pulmonary metastasis of melanoma cells. Oncogene 1997;14(24):2971-7.
17. Owen-Schaub LB, van Golen KL, Hill LL, Price JE. Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med 1998;188(9):1717-23.
18. Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999;59(18):4525-8.
19. Kim DH, Nelson HH, Wiencke JK, et al. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 2001; 20(14):1765-70.
20. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond.) 1996;379(6560): 88-91.
21. Kim CY, Tsai MH, Osmanian C, et al. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res 1997; 57(19):4200-4.
22. Mirnezami AH, Campbell SJ, Darley M, Primrose JN, Johnson PW, Blaydes JP. Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription. Curr Biol 2003;13(14):1234-9.
23. Zhu Y, Mao XO, Sun Y, Xia Z, Greenberg DA. p38 mitogen-activated protein kinase mediates hypoxic regulation of Mdm2 and p53 in neurons. J Biol Chem 2002; 277(25):22909-14.
24. Alarcon R, Koumenis C, Geyer RK, Maki CG, Giaccia AJ. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res 1999;59(24):6046-51.
25. 1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994;14(9): 6264-77.
26. Soengas MS, Alarcon RM, Yoshida H, et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science (Wash. DC) 1999;284(5411):156-9.
27. Rossler J, Schwab M, Havers W, Schweigerer L. Hypoxia promotes apoptosis of human neuroblastoma cell lines with enhanced N-myc expression. Biochem Biophys Res Commun 2001;281(2):272-6.
28. Harris AL. Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2(1):38-47.
29. Jang A, Hill RP. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. Clin Exp Metastasis 1997;15(5):469-83.
30. Cairns RA, Kalliomaki T, Hill RP. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res 2001;61(24):8903-8.
31. De Jaeger K, Kavanagh MC, Hill RP. Relationship of hypoxia to metastatic ability in rodent tumours. Br J Cancer 2001;84(9):1280-5.
32. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993;13(7):4107-14.
33. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7(7A):1126-32.
34. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993;12(2):461-8.
35. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature (Lond.) 1995;378(6553):206-8.
36. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (Lond.) 1995;378(6553):203-6.
37. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 1996;2(8):912-7.
38. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature (Lond.) 1997;387(6630):299-303.
39. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420(1):25-7.
40. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998; 17(2):554-64.
41. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 1998;95(26):15608-12.
42. Tao W, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 1999;96(6):3077-80.
43. Hill RP, Farkas-Himsley H. Further studies of the action of a partially purified bacteriocin against a murine fibrosarcoma. Cancer Res 1991;51(5):1359-65.
44. Rice GC, Spiro IJ, Ling CC. Detection of S-phase overreplication following chronic hypoxia using a monoclonal anti-BrdUrd. Int J Radiat Oncol Biol Phys 1985;11(10): 1817-22.
45. Cillo C, Dick JE, Ling V, Hill RP. Generation of drug-resistant variants in metastatic B 16 mouse melanoma cell lines. Cancer Res 1987;47(10):2604-8.
46. Young SD, Hill RP. Effects of reoxygenation on cells from hypoxic regions of solid tumors: analysis of transplanted murine tumors for evidence of DNA overreplication. Cancer Res 1990;50(16):5031-8.
47. Coquelle A, Rozier L, Dutrillaux B, Debatisse M. Induction of multiple double-strand breaks within an hsr by meganucleasel-Scel expression or fragile site activation leads to formation of double minutes and other chromosomal rearrangements. Oncogene 2002;21(50):7671-9.
48. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991;51(17): 4716-20.
49. 1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 1996;16(5):2445-52.
50. Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003;3(2):102-9.
51. Vousden KH. p53: death star. Cell 2000;103(5):691-4.
52. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2(9):647-56.
53. Suzuki N, Withers HR. Lung colony formation: a selective cloning process for lung-colony-forming ability. Br J Cancer 1979;39(2):196-9.
54. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature (Lond.) 1997;387(6630):296-9.
55. Polsky D, Bastian BC, Hazan C, et al. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 2001; 61(20):7642-6.
56. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26(15):3453-9.
57. Leite KR, Franco MF, Srougi M, et al. Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol 2001;14(5):428-36.
58. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 2002;21(17):2750-61.
59. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54(3):794-9.
60. Koumenis C, Naczki C, Koritzinsky M, et al. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol Cell Biol 2002;22(21): 7405-16.
61. Blagosklonny MV, Demidenko ZN, Fojo T. Inhibition of transcription results in accumulation of Wt p53 followed by delayed outburst of p53-inducible proteins: p53 as a sensor of transcriptional integrity. Cell Cycle 2002;1(1):67-74.
62. Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000;20(9):3224-33.
63. Chen D, Li M, Luo J, Gu W. Direct interactions between HIF-1alpha and Mdm2 modulate p53 function. J Biol Chem 2003;278(16):13595-8.
64. Wu L, Levine AJ. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol Med 1997;3(7):441-51.
65. Chang NS. The non-ankyrin C terminus of Ikappa Balpha physically interacts with p53 in vivo and dissociates in response to apoptotic stress, hypoxia, DNA damage, and transforming growth factor-beta 1-mediated growth suppression. J Biol Chem 2002;277(12):10323-31.
66. Ries S, Biederer C, Woods D, et al. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000;103(2):321-30.
67. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. p53 stabilization is decreased upon NF-kappaB activation: a role for NF-kappaB in acquisition of resistance to chemotherapy. Cancer Cell 2002;1(5):493-503.